Current Status and Future Directions of Immuncheckpoint Inhibitors for the Treatment of Urologic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 September 2021) | Viewed by 9883
Special Issue Editor
Interests: supportive care in cancer; bone metastases; side effects of immune checkpoint inhibitors; multiple myeloma; advanced bladder cancer; metastatic kidney cancer; metastatic prostate cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
Immune-checkpoint inhibitors (ICI) have become a cornerstone in the treatment armamentarium for patients with urothelial and renal cell carcinoma.
In metastatic urothelial cancer, PD-1 and PD-L1 inhibitors represent an effective second-line treatment option and offer a valid alternative to chemotherapy in the first line setting for cisplatin-ineligible patients. More recently, the PD-1 inhibitor pembrolizumab has also been approved for Bacillus Calmette–Guerin (BCG)-unresponsive, high-risk non-muscle invasive bladder cancer.
In addition to the PD-1 inhibitor nivolumab in patients progressing on anti-angiogenesis agents, current standard immunotherapy for advanced treatment-naïve kidney cancer includes a CTLA-4 blockade with ipilimumab, as well as combinations of the tyrosine-kinase inhibitor axitinib with either pembrolizumab or the PD-L1 antagonist avelumab.
Clinical trials are currently investigating the interplay of ICI with chemotherapy, hormone antagonists, and novel targeted agents, as well as surgical procedures. Research efforts are also directed to potentiating the response in prostate cancers and germ cell tumors and to identifying predictive biomarkers for optimal patient selection.
This Special Issue aims at covering the recent advances and future challenges of ICI-based strategies in urologic cancers, original and review articles are welcomed.
Dr. Sonia Vallet
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immuncheckpoint inhibitors
- kidney cancer
- bladder cancer
- prostate cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.